11Jan
[Articles] Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
The addition of opicapone 50 mg to levodopa treatment in patients with Parkinson's disease and end-of-dose motor fluctuations could enable a simplified drug regimen that allows physicians to individually tailor the existing levodopa daily regimen, by potentially reducing the total daily levodopa dose, increasing the dosing interval, and ultimately reducing the number of intakes, thereby maximising its benefit.
Ander nieuws
20May
[Comment] A new step towards targeting tau
Progressive supranuclear palsy is a rare neurodegenerative disease characterised by an axial parkins...
20May
[Review] CSF and blood biomarkers for Parkinson’s disease
In the management of Parkinson's disease, reliable diagnostic and prognostic biomarkers are urg...
22Apr
Parkinson’s disease patient: ‘I can walk… it’s really helped me’
Parkinson's disease patient Gail Jardine can walk more freely after having a spinal implant fit...